Neuropace
NPCE
32 hedge funds and large institutions have $91.2M invested in Neuropace in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 14 reducing their positions, and 15 closing their positions.
0.45% more ownership
Funds ownership: 74.42% → 74.88% (+0.45%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
20% less funds holding
Funds holding: 40 → 32 (-8)
39% less capital invested
Capital invested by funds: $150M → $91.2M (-$58.3M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
57% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$6.27M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$595K |
| 3 |
Millennium Management
New York
|
+$554K |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$254K |
| 5 |
E
Ergoteles
New York
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.07M |
| 2 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
-$1.64M |
| 3 |
RCM
Revelation Capital Management
Sausalito,
California
|
-$876K |
| 4 |
State Street
Boston,
Massachusetts
|
-$504K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$476K |
NPCE Hedge Fund Activity: Q2 2022 in Review
32 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q2 2022, worth a combined $91.2M — down 39% from $150M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of NPCE and 8 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 6 added.
The largest buyer was Morgan Stanley, adding an estimated $6.27M. The largest seller was BlackRock, cutting an estimated $2.07M.
- 32 institutional investors held Neuropace (NPCE) as of Q2 2022, down from 40 in Q1 2022.
- Funds reported $91.2M of Neuropace stock for Q2 2022, down 39% quarter-over-quarter.
- 8 funds opened new Neuropace positions in Q2 2022 and 15 closed out, a net change of -7 holders.
- The largest Neuropace buyer in Q2 2022 was Morgan Stanley, an estimated $6.27M added.
- The largest Neuropace seller in Q2 2022 was BlackRock, an estimated $2.07M sold.
Based on aggregated 13F filings for Q2 2022.